Hemant Surgical Industries Fair Value
Fair Value Analysis Export
P/B Based Valuation
Asset-Based Valuation
HSIL Fair Value Analysis — Data Sources & Coverage
Hemant Surgical Industries financial data sources, valuation methods applied and sector benchmarks used. For live price and a broader fundamental view, visit Hemant Surgical Industries stock price NSE.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
HSIL vs Healthcare Sector Peers — P/E, P/B & Market Cap
Hemant Surgical Industries P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Emcure Pharmaceuticals | EMCURE | 35.85 | 7.38 | ₹37,156 |
| Divis Laboratories | DIVISLAB | 84.36 | 14.72 | ₹244,125 |
| Aurobindo Pharma | AUROPHARMA | 25.97 | 2.54 | ₹96,479 |
| Syngene International | SYNGENE | 65.37 | 2.98 | ₹14,538 |
| Sat Kartar Life | SATKARTAR | 16.56 | 4.14 | ₹307 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.